Logical Therapeutics: Better medicine. It's only logical.

LT-NS001

LT-NS001 is the first in a family of bio-activated NSAID prodrugs. LT-NS001 is being developed to reduce the risk of gastric ulcers in patients who require an NSAID for the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the bloodstream, it is converted rapidly and quantitatively to naproxen.

In a Phase I / II double-blind, randomized, active comparator study of LT-NS001 vs. naproxen, in volunteers 45 to 70 years of age, subjects receiving LT-NS001 experienced a 79% reduction in the rate of gastric ulcers, and fewer gastric and duodenal erosions, when compared with subjects receiving Naprosyn® (naproxen).   Overall, subjects in the naproxen arm had 29 total ulcers, while only 3 ulcers were seen in the LT-NS001 arm.  Importantly, subjects dosed with LT-NS001 or naproxen twice daily for seven days had plasma concentrations of naproxen that were not different. These clinical studies confirm pre-clinical findings in rats and dogs, where LT-NS001 caused significantly less damage to the upper and lower gastrointestinal tract than equimolar doses of naproxen.

 

In addition to LT-NS001, Logical Therapeutics' pipeline includes additional NSAID prodrugs utilizing the same bio-activated technology found in LT-NS001. Each of these compounds will address significant unmet medical needs by providing physician's with a choice of GI-safer NSAIDs to best fit with their patient's optimal NSAID response.